tetano
Editor, Senior Moderator
MMWR Morb Mortal Wkly Rep
. 2024 Oct 3;73(39):861-868.
doi: 10.15585/mmwr.mm7339a1. Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024
Erica E Zeno, Francisco Nogareda, Annette Regan, Paula Couto, Marc Rondy, Jorge Jara, Carla Voto, Maria Paz Rojas Mena, Nathalia Katz, Maria Del Valle Juarez, Estefanía Benedetti, Francisco José de Paula Júnior, Walquiria Aparecida Ferreira da Almeida, Carlos Edson Hott, Paula Rodríguez Ferrari, Natalia Vergara Mallegas, Marcela Avendaño Vigueras, Chavely Domínguez, Marta von Horoch, Cynthia Vazquez, Eduardo Silvera, Hector Chiparelli, Natalia Goni, Laura Castro, Perrine Marcenac, Rebecca J Kondor, Juliana Leite, Martha Velandia, Eduardo Azziz-Baumgartner, Ashley L Fowlkes, Daniel Salas; REVELAC-i Network
Collaborators, Affiliations
To reduce influenza-associated morbidity and mortality, countries in South America recommend annual influenza vaccination for persons at high risk for severe influenza illness, including young children, persons with preexisting health conditions, and older adults. Interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries can provide early information about the protective effects of vaccination and help guide Northern Hemisphere countries in advance of their season. Using data from a multicountry network, investigators estimated interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalization using a test-negative case-control design. During March 13-July 19, 2024, Argentina, Brazil, Chile, Paraguay, and Uruguay identified 11,751 influenza-associated SARI cases; on average, 21.3% of patients were vaccinated against influenza, and the adjusted VE against hospitalization was 34.5%. The adjusted VE against the predominating subtype A(H3N2) was 36.5% and against A(H1N1)pdm09 was 37.1%. These interim VE estimates suggest that although the proportion of hospitalized patients who were vaccinated was modest, vaccination with the Southern Hemisphere influenza vaccine significantly lowered the risk for hospitalization. Northern Hemisphere countries should, therefore, anticipate the need for robust influenza vaccination campaigns and early antiviral treatment to achieve optimal protection against influenza-associated complications.
. 2024 Oct 3;73(39):861-868.
doi: 10.15585/mmwr.mm7339a1. Interim Effectiveness Estimates of 2024 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Hospitalization - REVELAC-i Network, Five South American Countries, March-July 2024
Erica E Zeno, Francisco Nogareda, Annette Regan, Paula Couto, Marc Rondy, Jorge Jara, Carla Voto, Maria Paz Rojas Mena, Nathalia Katz, Maria Del Valle Juarez, Estefanía Benedetti, Francisco José de Paula Júnior, Walquiria Aparecida Ferreira da Almeida, Carlos Edson Hott, Paula Rodríguez Ferrari, Natalia Vergara Mallegas, Marcela Avendaño Vigueras, Chavely Domínguez, Marta von Horoch, Cynthia Vazquez, Eduardo Silvera, Hector Chiparelli, Natalia Goni, Laura Castro, Perrine Marcenac, Rebecca J Kondor, Juliana Leite, Martha Velandia, Eduardo Azziz-Baumgartner, Ashley L Fowlkes, Daniel Salas; REVELAC-i Network
Collaborators, Affiliations
- PMID: 39361525
- PMCID: PMC11449270
- DOI: 10.15585/mmwr.mm7339a1
To reduce influenza-associated morbidity and mortality, countries in South America recommend annual influenza vaccination for persons at high risk for severe influenza illness, including young children, persons with preexisting health conditions, and older adults. Interim estimates of influenza vaccine effectiveness (VE) from Southern Hemisphere countries can provide early information about the protective effects of vaccination and help guide Northern Hemisphere countries in advance of their season. Using data from a multicountry network, investigators estimated interim VE against influenza-associated severe acute respiratory illness (SARI) hospitalization using a test-negative case-control design. During March 13-July 19, 2024, Argentina, Brazil, Chile, Paraguay, and Uruguay identified 11,751 influenza-associated SARI cases; on average, 21.3% of patients were vaccinated against influenza, and the adjusted VE against hospitalization was 34.5%. The adjusted VE against the predominating subtype A(H3N2) was 36.5% and against A(H1N1)pdm09 was 37.1%. These interim VE estimates suggest that although the proportion of hospitalized patients who were vaccinated was modest, vaccination with the Southern Hemisphere influenza vaccine significantly lowered the risk for hospitalization. Northern Hemisphere countries should, therefore, anticipate the need for robust influenza vaccination campaigns and early antiviral treatment to achieve optimal protection against influenza-associated complications.